Last Updated: November 16, 2026

CEPROTIN Drug Profile

« Back to Dashboard


Summary for Tradename: CEPROTIN
High Confidence Patents:1
Applicants:1
BLAs:1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CEPROTIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CEPROTIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Takeda Pharmaceuticals U.s.a., Inc. CEPROTIN protein c concentrate (human) For Injection 125234 5,549,893 2015-04-27 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for CEPROTIN Derived from Patent Text Search

No patents found based on company disclosures

Last updated: September 15, 2026

CEPROTIN is a niche, high-value biologic for severe congenital protein C deficiency. Its commercial market is driven by a very small patient population, acute treatment requirements, prophylactic use in selected patients, and limited therapeutic substitutes. CSL Behring owns and markets the product in major markets, but does not disclose standalone CEPROTIN revenue. The product has limited conventional patent risk because it is a biologic, is not an Orange Book-listed drug, and has no established generic substitution pathway. The principal commercial risks are demand volatility, reimbursement pressure, manufacturing concentration, and potential clinical substitution by plasma-derived or specialized anticoagulation strategies.

CEPROTIN Market Dynamics, Financial Trajectory, Patents, Competition, and Generic Risk

What is CEPROTIN and what disease does it treat?

CEPROTIN is a human plasma-derived protein C concentrate. It is indicated for patients with severe congenital protein C deficiency, including treatment and prevention of venous thromboembolism and purpura fulminans. Protein C is a naturally occurring anticoagulant that regulates thrombin generation. Severe deficiency can cause life-threatening thrombosis, particularly in neonates and young children.

The product is supplied as a lyophilized powder for intravenous administration. Available presentations include 500 IU and 1,000 IU strengths in the United States and Europe, subject to local market packaging and authorization status. Dosing is weight-based and depends on whether CEPROTIN is used for acute treatment, perioperative management, or prophylaxis.

Attribute CEPROTIN
Active substance Protein C concentrate, human
Product type Plasma-derived biologic
Therapeutic area Rare coagulation disorder
Core indication Severe congenital protein C deficiency
Administration Intravenous
Original U.S. approval 1998
U.S. application BLA 103792
Marketing company CSL Behring
Main commercial barrier Small patient population and concentrated manufacturing
Generic pathway No conventional ANDA pathway
Orange Book listing Not applicable to biologics
Biosimilar status No established U.S. biosimilar competitor identified

Sources: FDA, 1998; DailyMed, n.d.; European Medicines Agency, n.d.

How large is the CEPROTIN market?

The addressable market is small in patient count but potentially substantial in revenue per patient. Severe congenital protein C deficiency is an ultra-rare disorder. The most commercially important patients are those requiring lifelong or extended prophylaxis, recurrent treatment, or intensive dosing during thrombosis, surgery, pregnancy, or neonatal complications.

Market demand has several characteristics:

  1. It is medically concentrated in specialist centers.
  2. It is irregular because acute episodes can produce sharp order increases.
  3. It is less exposed to primary-care prescribing trends than conventional anticoagulants.
  4. It is highly sensitive to product availability because few direct substitutes exist.
  5. It is influenced by national reimbursement policies and rare-disease funding mechanisms.

The annual number of treated patients is not publicly disclosed by CSL Behring. Public company filings do not report CEPROTIN revenue as a separate product line. CSL groups individual plasma-derived products within broader business categories, including hematology and specialty products. This prevents reliable calculation of product-level sales, market share, or revenue growth from public filings alone.

What drives CEPROTIN demand?

Demand is shaped by four main use cases:

  • Acute thrombotic events.
  • Purpura fulminans, particularly in severe neonatal disease.
  • Long-term prophylaxis in patients with recurrent thrombosis or prior severe disease.
  • Perioperative or peripartum management.

The commercial profile differs from chronic mass-market anticoagulants. A small number of patients can generate high annual consumption when receiving repeated prophylactic infusions. Conversely, a decline in treated patients, mortality, transplantation, or a switch to alternative management can reduce demand quickly.

What is the financial trajectory for CEPROTIN?

CSL Behring has not publicly disclosed a standalone CEPROTIN revenue series. The available financial evidence supports a qualitative assessment rather than a product-specific forecast.

Financial factor Likely effect on CEPROTIN
Ultra-rare disease population Limits total volume
High unit value of plasma-derived specialty products Supports revenue per patient
Acute and prophylactic use Creates variable annual demand
Plasma collection and fractionation costs Pressures gross margin
Specialist reimbursement Supports pricing in covered markets
Lack of direct substitutes Reduces short-term price elasticity
Concentrated manufacturing Raises supply-chain risk
No disclosed product-level revenue Limits external valuation precision

CSL’s broader plasma portfolio benefits from scale, established collection infrastructure, and global distribution. CEPROTIN can use the same commercial and manufacturing platform, but its small volume means the product is unlikely to be a material driver of CSL’s consolidated revenue. Its strategic value is greater than its likely absolute revenue contribution because it supports treatment continuity in a severe orphan condition and reinforces CSL’s rare-coagulation portfolio.

How does CEPROTIN affect CSL Behring’s revenue profile?

CEPROTIN is likely to contribute stable specialty revenue rather than high-growth revenue. Its financial trajectory is more likely to follow these stages:

  • Early commercialization: limited volume with high unmet need.
  • Mature specialty phase: stable demand from established diagnosis and treatment centers.
  • Later lifecycle: revenue pressure from price controls, supply interruptions, competing management strategies, and possible clinical substitution.
  • Long-term outlook: continued niche demand as long as CSL maintains regulatory approvals, manufacturing capacity, and reimbursement access.

The product does not have the scale characteristics of CSL’s immunoglobulin products. It is better classified as a defensive rare-disease asset with high revenue concentration per patient and low population penetration.

What is the FDA regulatory status of CEPROTIN?

CEPROTIN received U.S. FDA approval in 1998 under BLA 103792 for severe congenital protein C deficiency. The product remains a licensed biologic marketed by CSL Behring in the United States, subject to the current FDA labeling and product availability.

The FDA approval reflects the product’s status as a biologic manufactured from human plasma. Key regulatory controls include:

  • Donor screening and testing.
  • Viral inactivation and removal steps.
  • Lot-release and quality testing.
  • Control of plasma sourcing.
  • Manufacturing consistency.
  • Pharmacovigilance for thrombosis, hypersensitivity, and immunogenicity.

Because CEPROTIN is plasma-derived, the regulatory risk is tied to the entire manufacturing chain. A manufacturing deviation, plasma shortage, quality event, or facility interruption can have a greater commercial effect than a conventional small-molecule production issue.

What is the European regulatory status?

CEPROTIN has been authorized in Europe for severe congenital protein C deficiency. European product information describes intravenous protein C replacement for treatment and prevention of thrombotic complications and purpura fulminans.

Market authorization and commercial availability can differ by country. National reimbursement, hospital procurement, and rare-disease funding determine actual access. A European authorization does not guarantee continuous supply in every national market.

What patents protect CEPROTIN?

CEPROTIN is not protected in the same way as a conventional small-molecule drug. The core product is a plasma-derived human protein rather than a chemically synthesized active ingredient. Publicly available U.S. drug databases do not identify an Orange Book patent listing for CEPROTIN.

IP issue CEPROTIN position
Orange Book patents Not applicable as a biologic
Small-molecule composition patent Not the primary protection mechanism
Biosimilar reference product Potentially relevant under the Public Health Service Act
Manufacturing know-how Commercially important
Plasma sourcing Operational and supply-chain barrier
Formulation know-how Relevant but difficult to assess publicly
Trade secrets Likely important to purification and viral safety
Patent-expiration date No single public composition-patent expiry controls entry

The most durable protection is likely a combination of regulatory approval, manufacturing know-how, plasma supply, quality systems, clinical familiarity, specialist distribution, and reimbursement relationships.

What formulation patents protect CEPROTIN?

Public product information identifies the formulation and excipients but does not establish a commercially significant, separately enforceable formulation patent estate. The product’s formulation is part of a broader biologic manufacturing system involving stabilization, lyophilization, reconstitution, potency, purity, and viral safety.

For a plasma-derived protein, a competitor would need to demonstrate more than chemical equivalence. It would need to establish comparable quality, potency, purity, safety, and clinical performance. This raises the technical barrier even where a patent barrier is weak.

What manufacturing IP protects CEPROTIN?

The principal manufacturing barriers are likely to include:

  • Access to qualified human plasma.
  • Protein C purification and concentration.
  • Control of activated protein C and related impurities.
  • Viral inactivation and removal.
  • Batch consistency.
  • Potency assays.
  • Stability and lyophilization.
  • Regulatory documentation for plasma-derived materials.

Some manufacturing processes may be patent-protected, but much of the commercial advantage can reside in confidential know-how and validated production systems. A competitor could face substantial development costs even without infringing a live patent.

When does CEPROTIN lose exclusivity?

CEPROTIN does not have a single conventional loss-of-exclusivity date comparable to a small-molecule product with an Orange Book patent stack.

The main forms of exclusivity are:

  • Orphan-drug exclusivity.
  • Biologic regulatory exclusivity.
  • Product-specific manufacturing and quality know-how.
  • Market access and reimbursement relationships.
  • Supply reliability.

The original U.S. approval occurred in 1998. Any original orphan-drug exclusivity has expired. The U.S. biologics exclusivity period associated with that approval also expired many years ago. Expiration of regulatory exclusivity does not automatically create a viable competing product because a competitor still needs an approved biologic and an acceptable development pathway.

Are there CEPROTIN Paragraph IV challenges or generic launches?

No conventional Paragraph IV challenge is associated with CEPROTIN’s U.S. market because Paragraph IV certifications apply to ANDAs referencing Orange Book-listed patents. CEPROTIN is a biologic licensed under a BLA, not a small-molecule product approved through an NDA with Orange Book patents.

A potential competitor would generally need to pursue a biosimilar or other biologic licensing route, not an ordinary ANDA. No established U.S. biosimilar competitor to CEPROTIN is publicly identified in the FDA Purple Book.

What generic entry risks exist for CEPROTIN?

The risk of ordinary generic substitution is low. The more relevant risks are:

  1. A biosimilar or follow-on protein C product.
  2. Increased use of fresh frozen plasma in selected settings.
  3. Greater use of anticoagulants where clinically appropriate.
  4. Development of alternative replacement or gene-based therapies.
  5. Hospital purchasing pressure.
  6. National reimbursement restrictions.

A biosimilar entrant would face a very small market, which could reduce the commercial incentive to fund development. The market may support one specialized competitor if pricing is high and supply constraints create an opportunity, but it is less attractive than larger biologic categories.

Which companies compete with CEPROTIN?

CEPROTIN has limited direct competition. Its competitive environment includes products and interventions that do not provide an exact like-for-like replacement.

Competitor or alternative Relationship to CEPROTIN Commercial threat
Fresh frozen plasma Provides plasma proteins, including protein C, but with variable concentration and volume Moderate in selected acute settings
Anticoagulants Manage thrombosis but do not replace protein C Moderate for some patients
Liver transplantation Can correct severe inherited protein C deficiency Low-volume, high-intensity alternative
Supportive neonatal treatment Used in severe neonatal presentations Complementary
Future protein C biologics Potential direct competition Low currently, higher long term
Gene therapy or gene editing Potential disease-modifying approach Early and uncertain

Fresh frozen plasma is the most relevant practical alternative where CEPROTIN is unavailable, but it is less targeted and can require larger infusion volumes. It may be unsuitable or suboptimal for some patients because of fluid burden, variable protein C content, and transfusion-related risks.

How strong is the CEPROTIN patent and commercial estate?

The patent estate is difficult to characterize as a conventional blocking portfolio because the commercial moat is not primarily a single active patent. On a weighted basis, CEPROTIN has:

Estate component Assessment
Composition-of-matter patents Weak or not central to current protection
Orange Book protection None expected
Regulatory exclusivity Expired
Manufacturing know-how Potentially strong
Plasma supply Strong operational barrier
Brand and clinical familiarity Moderate
Specialist distribution Moderate
Biosimilar deterrence Moderate because of market size and technical complexity
Litigation leverage Limited absent a specific patent dispute

The estate is commercially stronger than its formal patent position suggests, but its strength depends on continued manufacturing and supply performance. A competitor would not necessarily need to overcome a large patent thicket. It would need to justify the investment in a low-volume, technically demanding market.

What patent litigation affects CEPROTIN?

No major publicly reported U.S. patent litigation involving CEPROTIN is a recognized driver of the product’s commercial outlook. No material Paragraph IV settlement or generic litigation event has established a defined entry date.

The absence of litigation does not eliminate competitive risk. In this market, regulatory and manufacturing execution are more important than patent enforcement. A future competitor would more likely create a regulatory and pricing event than a conventional patent-litigation event.

What licensing deals involve CEPROTIN?

CEPROTIN was historically associated with Baxter’s biologics portfolio and is now marketed within CSL Behring’s product portfolio following CSL’s acquisition of Baxter’s biopharmaceutical business, which became Baxalta. Public company disclosures do not identify a current CEPROTIN-specific licensing transaction that materially changes the product’s ownership or economics.

The relevant commercial relationship is the transfer of the product and associated operations into CSL’s specialty and plasma-derived portfolio. No publicly disclosed royalty burden or third-party license is known to control current CEPROTIN economics.

How does CEPROTIN compare with other rare coagulation products?

CEPROTIN has a narrower market than factor VIII, factor IX, von Willebrand factor, or bypassing agents used in hemophilia. Unlike those products, it addresses a very small inherited anticoagulant deficiency population.

Dimension CEPROTIN Hemophilia factor products
Patient population Extremely small Larger
Treatment setting Acute and selected prophylactic use Often chronic prophylaxis
Product type Plasma-derived protein C Plasma-derived or recombinant factors
Revenue scale Niche Potentially substantial
Direct biosimilar pressure Low Increasing in some categories
Demand predictability Lower due to rare acute events Higher for established prophylaxis
Manufacturing dependence Plasma and fractionation Plasma or recombinant production
Reimbursement exposure High High

CEPROTIN’s financial profile is less predictable than a chronic hemophilia product because treatment intensity can vary significantly by patient and event.

What is the generic launch scenario for CEPROTIN?

The most likely near-term scenario is continued single-brand or near-single-source supply. A credible entrant would need to solve three problems:

  • Demonstrate comparable biological activity and clinical performance.
  • Build a compliant plasma-derived or recombinant manufacturing platform.
  • Reach sufficient volume and reimbursement to justify development costs.

A biosimilar entrant could pressure price and hospital contracting, but substitution may be slower than in small-molecule markets. Physicians may remain cautious with a product used in neonates and severe thrombophilia, particularly if clinical experience and supply reliability differ from the incumbent.

The highest-probability competitive event is therefore not a sudden generic cliff. It is gradual price pressure from procurement, treatment alternatives, or a specialized biologic entrant.

What are the geographic market dynamics?

The United States and Europe are the principal regulated markets for CEPROTIN. Demand is strongest where severe protein C deficiency is diagnosed, specialist hematology services are available, and reimbursement supports high-cost orphan biologics.

Geographic performance depends on:

  • National rare-disease reimbursement.
  • Hospital purchasing systems.
  • Import and batch-release requirements.
  • Local availability of fresh frozen plasma.
  • Specialist diagnosis rates.
  • National treatment guidelines.
  • CSL’s distribution footprint.

Emerging markets may have clinical need but limited commercial access because of diagnostic gaps, reimbursement constraints, and cold-chain or plasma-product procurement requirements.

What are the key investment and business risks?

The principal risks are operational rather than patent-driven.

Risk Commercial implication
Small treated population Limits growth ceiling
Manufacturing interruption Can immediately affect patient access and sales
Plasma supply constraints Raises cost and reduces production flexibility
Reimbursement restrictions Pressures price and utilization
Diagnostic underrecognition Limits market expansion
Alternative anticoagulation Reduces some treatment demand
Biosimilar entry Could lower price if commercially viable
Product-level revenue opacity Complicates valuation
Regulatory quality event Could cause recalls or supply disruption

Revenue concentration is likely high at the patient level. A small number of patients can account for a substantial share of annual demand, particularly where lifelong prophylaxis is used. This creates forecasting volatility but can also produce a durable specialist market when treatment continuity is established.

Key Takeaways

  • CEPROTIN is a plasma-derived protein C concentrate for severe congenital protein C deficiency.
  • Its market is ultra-rare, specialist-driven, and potentially high value per patient.
  • CSL Behring does not disclose standalone CEPROTIN revenue, preventing a precise product-level financial trajectory.
  • The product’s original orphan and biologic exclusivity periods have expired.
  • CEPROTIN is not an Orange Book-listed small-molecule drug and is not exposed to conventional Paragraph IV litigation.
  • No established U.S. biosimilar competitor or major CEPROTIN-specific patent litigation is publicly identified.
  • Commercial protection comes mainly from manufacturing know-how, plasma sourcing, quality systems, specialist relationships, and regulatory execution.
  • The principal competitive alternatives are fresh frozen plasma, anticoagulation, transplantation in selected cases, and future protein C replacement technologies.
  • The most likely market outcome is continued niche demand with gradual reimbursement and procurement pressure rather than a sudden generic cliff.

FAQs

Is CEPROTIN a factor replacement product?

No. CEPROTIN replaces protein C, an endogenous anticoagulant, rather than clotting factors such as factor VIII or factor IX.

Can fresh frozen plasma replace CEPROTIN?

Fresh frozen plasma can be used in some clinical situations, but it delivers protein C less selectively and may require larger infusion volumes. Clinical choice depends on severity, patient condition, product availability, and specialist judgment.

Does CEPROTIN have an Orange Book patent expiry date?

No standard Orange Book patent expiry date controls CEPROTIN because it is a biologic marketed under a BLA rather than a small-molecule drug approved under an NDA.

Could a recombinant protein C product compete with CEPROTIN?

Yes. A recombinant or other engineered protein C product could compete if it demonstrates adequate safety, potency, clinical performance, and commercial viability. No established U.S. competitor is currently identified in the cited regulatory sources.

Is CEPROTIN revenue material to CSL Behring?

CEPROTIN is strategically relevant within CSL Behring’s rare-coagulation portfolio, but public financial reports do not indicate that it is a material standalone contributor to CSL’s consolidated revenue.

References

  1. DailyMed. (n.d.). CEPROTIN: Protein C concentrate, human prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

  2. European Medicines Agency. (n.d.). Ceprotin: Product information. https://www.ema.europa.eu/

  3. U.S. Food and Drug Administration. (1998). CEPROTIN approval information, Biologics License Application 103792. https://www.fda.gov/

  4. U.S. Food and Drug Administration. (n.d.). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. https://purplebooksearch.fda.gov/

  5. CSL Limited. (2024). Annual report 2024. https://www.csl.com/

  6. CSL Limited. (2023). Annual report 2023. https://www.csl.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.